RCUS - Arcus Biosciences Short-Term Debt to Capital

Symbol and logo of brand Arcus Bio (RCUS)

The linear price action on the Arcus Biosciences, Inc. (RCUS) chart, which shows a value of 0.03, is driven by a strategy of developing new drug combinations and a broad focus on various oncological diseases. High scientific authority and alliances with industry leaders confirm the brand's innovative status. Meanwhile, the business model relies on outsourcing all production stages and clinical trials, creating a strong dependency on third-party contractors.

Current Liabilities to Capital: Arcus Bio (RCUS) for 07/04/2022 - 10/31/2026

Summary analytical data breakdowns for arcusbio.com (RCUS)

- stock value and consensus price forecast:
Price Chart Arcus Bio|RCUS - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Arcus Biosciences Inc|RCUS - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share Arcus Biosciences|RCUS - Total Stockholders' Equity|Market Value to Book Value Ratio arcusbio.com|RCUS - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Arcus Biosciences, Inc.|RCUS - Long-Term Liabilities to Capital|Short-Term Debt to Capital Arcus Biosciences|RCUS - Company Total Indebtedness|Debt to Book Value Arcus Biosciences Inc|RCUS - Long-Term Debt|Company Current Liabilities Arcus Biosciences|Quick Ratio arcusbio.com
- company profitability and valuation multiples indicators:
RCUS - Net Financial Result
Initial company analysis:Arcus Bio RCUS
Signature product of arcusbio.com

Drug synthesis automation at Arcus Biosciences, Inc. (RCUS) accelerates development, yet costly clinical trials necessitate stable funding. By analyzing the ratio of short-term debt to equity, an investor assesses the business's dependence on obligations maturing within one year; a decline in this metric confirms balance sheet resilience, whereas an increase indicates heightened credit risks and a potential liquidity shortfall.

Competitors of Arcus Biosciences, Inc. (RCUS)

Short-Term Debt to Equity ImmunityBio Corp (IBRX)|Immunocore Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital JANX (Janux Therapeutics)|ZYME - Short-Term Debt to Equity Ratio|TNGX - Short-Term Debt to Equity|Current Liabilities to Capital Iovance Biotherapeutics Inc|Immatics Corp (IMTX) - Short-Term Debt to Equity|XNCR (Xencor Inc.) - Short-Term Debt to Equity|Short-Term Debt to Equity Compass Therapeutics|Current Liabilities to Capital replimune.com REPL|Short-Term Debt to Capital LYEL|Innate Pharma SA (IPHA) - Short-Term Indebtedness to Equity|Pyxis Oncology - Short-Term Debt to Equity Ratio|Compugen Ltd (CGEN) - Current Liabilities to Capital|IOBT: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital STRO (sutrobio.com)|INKT: Short-Term Debt to Capital|HOWL - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Immix Biopharma Inc.|Short-Term Debt to Equity Ratio alxoncology.com (ALXO)|Short-Term Debt to Equity Cue Biopharma (CUE)|Short-Term Debt to Equity Ratio pdsbiotech.com PDSB|Sonnet BioTherapeutics Holdings - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital MAIA Biotech MAIA|LIMN - Short-Term Debt to Equity|LVTX (LAVA Therapeutics N.V.) - Short-Term Debt to Capital Ratio|NextCure, Inc. (NXTC) - Short-Term Debt to Equity|Current Liabilities to Capital Leap Therapeutics (LPTX)|Short-Term Debt to Equity Ratio INTS|SNSE - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio TOVX (Synthetic Biologics)|Short-Term Loans to Capital Ratio GRTS|Short-Term Debt to Capital KA (Kineta, Inc.)|Ratio of Short-Term Indebtedness to Capital NEXI|Turnstone Biologics Corporation - Short-Term Debt to Capital|Current Liabilities to Capital Vaccinex Inc.|Harpoon Tx (HARP) - Short-Term Debt to Equity